Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial

Código QR

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial

Guardado en:

Detalles Bibliográficos
Autores principales:	Fengtan Li, Xifeng Dong
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a69bfb0defa04ea3b11f96a5ccff03e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
por: Kei Sonehara, et al.
Publicado: (2021)

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
por: Weinberg F, et al.
Publicado: (2019)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
por: Antoni Ribas, et al.
Publicado: (2020)

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus
por: Jie Qian, et al.
Publicado: (2021)

Keynote Speakers
por: Challenging Glass
Publicado: (2018)

Keynote Speakers
por: Challenging Glass
Publicado: (2016)

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Somasundaram A, et al.
Publicado: (2017)

Pembrolizumab-Induced Lichen Planus on the Scalp of a Patient with Non-Small-Cell Lung Carcinoma
por: Aya Yamashita, et al.
Publicado: (2021)

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
por: Noguchi S, et al.
Publicado: (2020)

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
por: Toshiki Ogiwara, et al.
Publicado: (2021)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
por: Qiao Liu, et al.
Publicado: (2021)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Qiao Liu, et al.
Publicado: (2021)

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
por: Hui Zheng, et al.
Publicado: (2021)

CT based radiomic approach on first line pembrolizumab in lung cancer
por: Marta Zerunian, et al.
Publicado: (2021)

Keynote Address to the International Seminar on Malik Bennabi
por: Anwar Ibrahim
Publicado: (1992)

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
por: Yahua Wu, et al.
Publicado: (2022)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Jie Zhang PhD, et al.
Publicado: (2021)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
por: Christine S Walsh, et al.
Publicado: (2021)

ECLAC keynotes for development No 3: Foreign Direct Investment
Publicado: (2018)

ECLAC keynotes for development No 1: Foreign Direct Investment
Publicado: (2017)

ECLAC keynotes for development No 4: International Trade Outlook
Publicado: (2019)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
por: Galina B. Statsenko, et al.
Publicado: (2020)

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
por: Meier EJ, et al.
Publicado: (2018)

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra RP, et al.
Publicado: (2019)

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
por: Youwen Zhu, et al.
Publicado: (2021)

Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
por: Motoyasu Kato, et al.
Publicado: (2021)

Cooperation among unrelated ant queens provides persistent growth and survival benefits during colony ontogeny
por: Madeleine M. Ostwald, et al.
Publicado: (2021)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis VM, et al.
Publicado: (2018)

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
por: Minami S, et al.
Publicado: (2017)

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
por: Dong Lin, et al.
Publicado: (2021)

Two randomized trials provide no consistent evidence for nonmusical cognitive benefits of brief preschool music enrichment.
por: Samuel A Mehr, et al.
Publicado: (2013)

Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
por: Satoru Taguchi, et al.
Publicado: (2021)

Design of 1 280×1 024 DI Multi-Functional IRFPA Readout Circuit
por: Qiu Tianhui, Xia Xiaojuan, Liu Qi, Guan Yu
Publicado: (2021)

Keynote address by the Minister of Finance of Trinidad and Tobago, the Honourable Brian Kue Tung
por: Tung, Brian Kuei
Publicado: (2014)

Afatinib treatment in advanced non-small cell lung cancer
por: Hurwitz JL, et al.
Publicado: (2011)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

Hypertrophic lichenoid dermatitis during pembrolizumab treatment
por: Ryoma Honda, et al.
Publicado: (2021)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Mary L Disis, et al.
Publicado: (2021)

Keynote Closing Address for EAC12: The Worldwide State of Experimental Archaeology and the Agenda for the Future
por: Linda Hurcombe, et al.
Publicado: (2021)

Educating Well: A Keynote on a Future Paradigm for Applied Arts and Health in Education
por: Ross W. Prior, et al.
Publicado: (2021)